All GLG News Analyses Filed Under: Infectious Disease

Many of our vaccines are not life-lasting. That the Hep B vaccine shows waning immunity should not be that much of a surprise. The real issue that needs to be addressed is what is the interval of immunity and who should be revacinnated.

This report notes the agreement between Bayer and Nektar for the further development and commercialization of inh amikacin for gram neg pneumonia. Recent presentations of their phase 2 randomized  studies looked at this product in addition to iv antibiotics for vent pneumonia with gram neg bacteria,...

I have long been concerned about this issue - not only for Hep B, but moreover for Varicella, and measles, etc.  It is my prediction that, before the end of my medical career, immunizations will take a greater part in the Family Medicine/Internal Medicine practices, and people will need to receive...

- this was a well-done although small study of oral fluconazole   in the treatment of seborrheic dermatitis - it showed no statistically significant benefit

Tibotec Pharmaceuticals Ltd. NDA for TMC125 etravirine is on the FDA "Fast Track" and should not be.

Although often ignored due to its complexity, the role of lymphatics is extremely important in determining the fluid balance not only in the lung, but also in the peripheral organs. This animal study underlines that it is important we open up - and keep open - the lymphatics, since they are the hydraulics...

The study showed efficacy and safety of a new drug TD-1792 once daily, compared to the comparator Vancomycin in complicated skin and soft tissue infcetions.  Both arms had just under 100 patients and had clinical cures over 90%, without major or unforeseen adverse reactions. It was a randomized,...

We are seeing more and more MRSA in both the hospital and community setting. We need more drugs that can combat this agent as we are now begining to see early resistance or side effcts from existing agents. If this drug holds uo in Phase 3 it would be a welcome addition and likely obtain a resonable...

- respiratory syncytial virus and parainfluenza virus are common   causes of severe respiratory tract infection in young children - there is currently no vaccine for either - a safe vaccine for both would become mandatory in all probability

-Rotarix (rotavirus vaccine) has been submitted for approval by Glaxo -Merck's Rotateq has been on the market for over a year now and has contracts with major players already in place -By the time GSK gets marketing approval, it will be a long time before they can convince enough clients to change ...